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Abstract 
Depressive symptoms (e.g., anhedonia) have been observed in cannabis users. Alterations in 
delay discounting have been observed in depressed individuals. Steep discounting (i.e., 
impulsive choice) has been associated with tobacco, alcohol, and cocaine abuse, but not cannabis 
abuse. This study evaluated the association between anhedonia, cannabis use, and delay 
discounting. Participants (329 undergraduates) were assessed for marijuana use patterns (age of 
first use, weekly dose, MPS, DSM-V CUD), anhedonia (SHAPS), and delay discounting 
(impulsivity) using an online Qualtrics survey to determine the covariation among these 
variables. Anhedonia and measures of marijuana use were not significantly associated and 
neither measure was significantly associated with delay discounting. Significant correlations 
were observed primarily among marijuana use measures. In multiple regression analysis, neither 
anhedonia nor marijuana use amount was a significant predictor of delay discounting. A 
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Introduction 
 Marijuana is the most commonly used illicit drug not only in the United States, but also 
worldwide (Cooper & Haney, 2008). As prevalence of use has increased in recent years, so too 
has the prevalence of cannabis use disorder (Hasin et al., 2015). According to the DSM-IV, 
cannabis dependence is characterized by psychosocial interferences including using cannabis in 
larger amounts or over a longer period than intended, the inability to reduce cannabis use, and 
neglecting important social or occupational obligations in favor of using cannabis (Blanco et al., 
2008). Cannabis use has been associated with psychological impairments related to attention, 
working memory, and decision-making (Heishman et al., 1997; Miller et al., 1977; Ramaekers et 
al., 2006; Morrison et al., 2009). Furthermore, there is an extensive literature suggesting that 
symptoms of major depressive disorder are prevalent among cannabis users (Grant et al., 1995; 
Repetto et al., 2008; Horwood et al., 2012). 
 The discounting of delayed rewards is often studied in depressed populations (Beck, 
1979; Pulcu et al., 2014). Depressed individuals tend to discount the value of delayed rewards 
differently than that of healthy controls, perhaps due to characteristic depressive symptoms 
including hopelessness and loss of pleasure (Beck, 1979; Berenbaum & Oltmanns, 1992; Wacker 
et al., 2009; Lempert & Pizzagalli, 2010; Pulcu et al., 2014). Furthermore, there is extensive 
evidence concluding that steeper discounting of delayed rewards is observed among individuals 
with dependence on substances including tobacco, alcohol, and cocaine (Yi, Mitchell, & Bickel, 
2010). The limited literature regarding delay discounting among cannabis-dependent individuals 
suggests that there may be a modest association, perhaps not as strong as the association among 
discounting and substances with greater abuse-related properties (Johnson et al., 2010; Peters et 
al., 2013). 
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Cannabis Use, Abuse, and Dependence 
Assessment Surveys 
 There are a variety of instruments available to assess factors related to marijuana use. The 
Marijuana Use Form (MUF) inquires whether participants have ever used marijuana, date of 
most recent marijuana use, and use frequency within the past month as well as over the lifetime 
(Buckner, Bonn-Miller, Zvolensky, & Schmidt, 2007). While the MUF only measures use 
patterns, other instruments have been developed to assess potentially adverse consequences of 
long-term marijuana use. The Marijuana Problems Scale (MPS) is a nineteen-item survey that 
assesses the social, occupational, physical, and personal consequences related to marijuana use 
within the last ninety days (Buckner, Bonn-Miller, Zvolensky, & Schmidt, 2007). Even further 
than measuring negative consequences associated with marijuana use, the Marijuana Motives 
Measure (MMM) aims to determine the individual’s reasons for choosing to use marijuana; 
participants use a five-point Likert-type scale to indicate the degree to which they have used 
marijuana for reasons including coping, social connection, conformity, cognitive enhancement, 
and awareness expansion (Buckner, Bonn-Miller, Zvolensky, & Schmidt, 2007). 
Need a short summary paragraph here on these scales – is there any consensus on one being 
‘best’ or most sensitive, etc. 
Prevalence 
 Cannabis is the most frequently used illicit drug not only in the United States, but 
globally as well (Cooper & Haney, 2008). In recent years, twenty-three states have established 
medical marijuana protocols, four states have legalized cannabis for recreational use, and overall 
support for legalization has increased (Hasin et al., 2015). Marijuana use in the United States 
increased from 4.1 percent of the population in 2002 to 9.5 percent of the population in 2013 
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(Hasin et al., 2015). Accordingly, the prevalence of DSM-IV cannabis use disorder increased 
from 1.5 percent in 2002 to 2.9 percent in 2013, reflecting a statistically significant increase 
across all demographic subgroups (Hasin et al., 2015). However, the prevalence of cannabis use 
disorder among regular marijuana users decreased significantly from 2002 (35.6 percent) to 2013 
(30.6 percent) (Hasin et al., 2015). 
 
Mechanism of Action 
Neurochemistry 
 Among the hundreds of chemical compounds found in cannabis, tetrahydrocannabinol 
(THC) is regarded as the active ingredient for its psychoactive properties (Williamson, Buckland, 
& Cunningham, 2013). Common psychoactive effects include euphoria, depersonalization, 
altered sense of time, and intensification of sensory experiences (Anderson, Rizzo, Block, 
Pearlson, & O'Leary, 2010). THC produces these psychoactive effects by binding to cannabinoid 
receptors within the endocannabinoid system known as CB1 and CB2 (Solinas, Goldberg, & 
Piomelli, 2008). Binding to these receptors allows THC to mimic the effects of anandamide, an 
endogenous neurotransmitter (Schwarz, Blanco, & Lotz, 1994). CB1 receptors are abundant in 
areas of the brain responsible for memory, motor coordination, and emotionality (Solinas, 
Goldberg, & Piomelli, 2008). These receptors are located at presynaptic terminals within areas 
including the hippocampus, cerebellum, and prefrontal cortex, as well as regions of the 
mesolimbic dopamine system (Solinas, Goldberg, & Piomelli, 2008). While the large quantity of 
CB1 receptors deems them primarily responsible for the psychoactive effects of THC, CB2 
receptors also play an important role (Solinas, Goldberg, & Piomelli, 2008). CB2 receptors are 
primarily found in peripheral tissues and are sparsely dispersed throughout the brain and the 
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central nervous system (Bab et al., 2009). 
Mesolimbic Dopamine System 
Dopamine is a largely influential neurotransmitter that travels over many different 
pathways throughout the brain for a wide range of purposes (Puri, Hall, & Ho, 2013). Among the 
four major dopamine pathways are the nigrostriatal pathway, which moderates motor function 
and movement, the mesocortical pathway, which influences cognitive control and emotional 
response, and the tuberoinfundibular pathway, which is involved in hormone secretion (Puri, 
Hall, & Ho, 2013). This section will focus on the mesolimbic dopamine pathway, which is 
involved in regulating the reinforcing properties of pleasant stimuli (Puri, Hall, & Ho, 2013). 
Activity of the mesolimbic dopamine system is associated with unconditioned reinforcers 
for numerous adaptive activities including eating, drinking, mating, and social bonding (Pitchers 
et al., 2010). Beyond regulating the rewarding properties of natural reinforcers, dopaminergic 
cells in the ventral-tegmental area are also highly responsive to conditioned reinforcement 
(Cassidy & Shaver, 2016). In response to positive reinforcing stimuli, whether natural or 
conditioned, dopamine is transported from the ventral tegmental area to the nucleus accumbens 
and limbic regions of the amygdala, hippocampus, and medial prefrontal cortex (Pierce & 
Kumaresan, 2006). 
There is conclusive evidence that the mesolimbic dopamine system has a critical role in 
conditioning and regulating the rewarding effects of drugs of abuse in substance-dependent 
individuals (Levran et al., 2015). For instance, acute cocaine administration inhibits dopamine 
transporter proteins from removing dopamine neurotransmitters from the synaptic cleft (Hope, 
1997). As a result, the dopamine concentration within the synaptic cleft is drastically increased 
and in turn, dopaminergic receptors are rapidly activated (Hope, 1997). Repeated exposure to 
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substances with high abuse potential alters the neuronal composition and synaptic strength within 
the mesolimbic dopamine system, ultimately motivating the individual to continue using the 
substance (Pitchers et al., 2010). 
Following cocaine administration, its effects are experienced almost immediately and last 
only a short duration of time (Pierce & Kumaresan, 2006). These properties are conducive to the 
rapid formation of association between the reinforcer and its reinforcing effects across a variety 
of species, deeming cocaine a substance of high abuse potential (Pierce & Kumaresan, 2006). 
Conversely, the onset of cannabis effects is more drawn out and its effects tend to last longer, 
deeming cannabis a substance of lower abuse potential (Pierce & Kumaresan, 2006). Unlike 
cocaine and other drugs of higher abuse potential, mild to moderate cannabis use does not alter 
the composition of the mesolimbic dopamine system (Urban et al., 2012). However, decreased 
dopamine release has been observed in chronic cannabis users as well as those who began using 
during adolescence (Urban et al., 2012). 
Abuse Potential 
Abuse potential refers to the level at which a drug produces positive reinforcing effects 
and therefore motivates the user to continue using (Markgraf, Hudzik, & Compton, 2015). 
Virtually every drug abused by humans is also self-administered by nonhuman animals in a 
variety of laboratory models (Miller & Carroll, 2012). Animal models have high predictive 
validity, meaning that if laboratory animals repeatedly self-administer the drug then it will also 
has a high abuse liability in humans (Miller & Carroll, 2012). 
Regarding the abuse potential of cannabis, there is a discrepancy in the literature and 
therefore an animal model has not yet been established. One early study found that rhesus 
monkeys would not consistently self-administer various doses of THC, even though they had 
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previously been trained to self-administer cocaine as well as cocaine-THC mixtures (Harris, 
Waters, & McLendon, 1974). While a later study found that non-human animals would self-
administer THC, it is important to note that the animals were deprived of basic needs such as 
food and water; only under these deprived conditions would the animals self-administer THC, 
which is a measure that does not need to be taken in order for animals to self-administer drugs 
with higher abuse potentials (Cooper & Haney, 2008). In human laboratory studies, subjects are 
more likely to self-administer active marijuana compared to placebos, and marijuana with high 
THC levels compared to lower THC levels (Cooper & Haney, 2008). Human preference to 
administer marijuana with increasing THC levels supports the hypothesis that THC is the 
primary reinforcing agent in marijuana (Cooper & Haney, 2008). 
Dependence 
 The DSM-IV identifies cannabis abuse by continued failure to fulfill daily obligations, 
persistent substance-related legal problems, recurrent use at inappropriate times, and failure to 
stop using despite substance-related interpersonal problems (Thake & Davis, 2011). While 
cannabis abuse is characterized by psychological and social consequences of use, cannabis 
dependence also takes the biological features of substance use into account (Thake & Davis, 
2011). The DSM-IV recognizes cannabis dependence (CD) as fulfillment of at least three of the 
following six criteria at any time over a twelve-month period: “(1) development of tolerance; (2) 
using cannabis in larger amounts or over a longer period than intended; (3) inability to cut down 
or reduce cannabis use; (4) spending large amounts of time to obtain, use, or recover from the 
effects of cannabis; (5) giving up important social, occupational, or recreational activities in 
favor of using cannabis; (6) continued use of cannabis despite its adverse consequences” (Blanco 
et al., 2008). 
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It is estimated that only 9.1 percent of individuals who ever use cannabis in their lifetime 
develop dependence (Looby & Earleywine, 2007). While daily cannabis use increases the user’s 
risk of developing dependence, research indicates that a minority of daily users (20 to 50 
percent) are cannabis-dependent (Coffey et al., 2002; EMCDDA, 2009). Other conditions that 
may predict the development of cannabis dependence include early onset of use, dependence 
upon other substances such as nicotine, alcohol, and cocaine, family history of substance use 
disorders, and personality traits including impulsivity and aggression (Chen et al., 2005; Lopez-
Quintero et al., 2010; Von Sydow et al., 2002). These predictor variables are similar in that they 
are all stable vulnerability factors; however, conflicting research indicates that the development 
of cannabis dependence is attributable to current problematic circumstances rather than stable 
vulnerability conditions (Pol et al., 2013). Current circumstances that may predict cannabis 
dependence include living alone, using cannabis as a coping mechanism, and recent stressful life 
events, most often involving finances (Pol et al., 2013). While cannabis dependence is observed 
only in a small percentage of users (Looby & Earleywine, 2007; Coffey et al., 2002; EMCDDA, 
2009), the literature has identified cannabis use patterns as well as negative life circumstances 
that may contribute to the development of cannabis dependence (Chen et al., 2005; Lopez-
Quintero et al., 2010; Von Sydow et al., 2002; Pol et al., 2013). 
Although research regarding the variables contributing to cannabis dependence is 
inconclusive, it is important to recognize the distinction between dependent and non-dependent 
users. Non-dependent users are able to manage their use and experience little interference with 
other aspects of their lives, whereas dependent users experience significant psychosocial 
impairments as a result of their substance use (Looby & Earleywine, 2007). Common 
psychosocial problems experienced by dependent users include family problems, strained 
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romantic relationships, and increased absence at school or work (Looby & Earleywine, 2007). 
Overall, dependent users are characterized by uncontrolled use of the substance along with the 
psychosocial and motivational impairments that arise from frequent use (Coffey et al., 2002; 
Looby & Earleywine, 2007). 
Beyond distinguishing between dependent and non-dependent users, a distinction should 
also be made between problematic and non-problematic users (Thake & Davis, 2011). Many 
individuals who do not meet criteria for abuse or dependence nonetheless experience problems 
and impairments indirectly resulting from frequent cannabis use (Caldeira et al., 2008; Davis et 
al., 2009). Beck and Legleye (2008) pioneered the development of a problematic cannabis use 
threshold, in which problematic use is characterized by negative health or social outcomes for 
the individual or the larger community. Similarly, Davis and colleagues (2009) define 
problematic cannabis use as a series of use patterns that is indirectly detrimental to the user 
socially, physically, financially, and occupationally. In their study, it was found that although 
weekly cannabis use increased the risk of experiencing use-related problems, only two-thirds of 
those who used at least weekly reported use-related problems (Davis, Thomas, Jesseman, & 
Mazan, 2009). In addition to higher use frequency, other characteristics that may predict 
problematic use are using in the morning, using as a coping mechanism, experiencing depression 
or guilt, and engaging in risky behaviors such as driving under the influence (Annaheim et al., 
2008; Davis et al., 2009; Legleye et al., 2007). Conclusively, more frequent cannabis use 
increases the risk of experiencing use-related problems, but frequent cannabis use – even on a 
weekly basis – does not explicitly cause problematic use, abuse, or dependence (Thake & Davis, 
2011). 
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Withdrawal 
 A consensus has not been reached regarding whether cessation of regular use produces a 
distinctive cannabis withdrawal syndrome (Milin, 2008). Although the DSM-IV does not 
currently acknowledge diagnostic criteria for cannabis withdrawal syndrome, there is 
preliminary evidence suggesting that abrupt cessation of cannabis use produces unpleasant 
psychological withdrawal symptoms (Milin, 2008). Reported withdrawal symptoms include 
mood changes, increased anxiety, irritability, aggressiveness, disturbed sleep, and more 
infrequently, physical symptoms such as headaches, upset stomach, nausea, and discomfort 
(Milin, 2008; Levin et al., 2010). 
It is noteworthy that not all individuals who use cannabis experience withdrawal 
symptoms upon cessation; one study found that only 42.4 percent of participants reported 
incidence of cannabis withdrawal (Levin et al., 2010). Participants who used marijuana more 
frequently on a daily, weekly, and monthly basis reported more severe withdrawal symptoms, 
while no significant correlation was found between withdrawal symptoms and race, age, history 
of tobacco dependence, or other cannabis use variables (Levin et al., 2010). Furthermore, 
significant associations were found between high tolerance and instance of withdrawal 
symptoms (Levin et al., 2010). In instances where no withdrawal symptoms are reported, it is 
theorized that THC’s properties of easily storing in fat tissue and releasing slowly prevent the 
user from experiencing withdrawal symptoms (Tanda & Goldberg, 2003). 
Overall, some users have reported withdrawal symptoms following cessation of cannabis 
use (Milin, 2008; Levin et al., 2010). Additionally, instance of withdrawal symptoms seems to be 
associated with frequency of use and level of tolerance (Levin et al., 2010). However, not all 
cannabis users experience a withdrawal syndrome (Levin et al., 2010; Tanda & Goldberg, 2003) 
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and cannabis withdrawal syndrome has yet to be recognized by the DSM-IV (Milin, 2008). 
 
Psychological Impact 
Cannabis use has been shown to impair an array of executive functions, which include 
learning, memory, attention, and problem-solving (Crean, Crane, & Mason, 2011). The level of 
impairment differs depending on age at onset, frequency, quantity, and duration of marijuana use 
(Crean, Crane, & Mason, 2011). Certain executive functions may return to normal levels at 
cessation of marijuana use, while other impairments have more long-term impacts (Crean, Crane, 
& Mason, 2011). It has been found that after three weeks of abstinence, cannabis users exhibited 
enduring impairments in decision-making, concept formation, and planning, while basic 
attention and memory functions returned to normal (Crean, Crane, & Mason, 2011). The 
literature is inconclusive regarding whether low-to-moderate recreational marijuana users will 
experience long-term cognitive impacts (Jager et al., 2006). Furthermore, research indicates that 
heavy cannabis users often accumulate a high tolerance for THC, resulting in little to no 
impairment of executive functions (Ramaekers et al., 2011). 
Attention 
 Attentional processing refers to the ability to focus on a target stimulus in both divided 
and sustained attention tasks (Grady, 1999). Research indicates that non-experienced cannabis 
users experience greater attentional impairment than individuals who use cannabis regularly 
(Morrison et al., 2009). Interestingly, regular cannabis users perform better in both sustained and 
divided attention tasks following THC administration rather than an abstinence period (Hart, van 
Gorp, Haney, Foltin, & Fischman, 2001). 
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Working Memory 
 The present literature is conclusive that acute cannabis use significantly impairs the 
ability to retain, manipulate and recall information after a short delay, even in regular cannabis 
users (Heishman et al., 1997; Miller et al., 1977). However, there seems to be no long-term 
impact on working memory; one study found no significant differences in working memory 
ability between non-users and cannabis users of low to high frequencies following an abstinence 
period of only 19 hours (Pope & Yurgelun-Todd, 1996). 
Decision-Making 
 The current literature presents a discrepancy regarding whether acute cannabis use leads 
to disruptions in decision-making (Crean, Crane, & Mason, 2011). Ramaekers et al. (2006) 
conducted a study in which regular cannabis users were asked to perform a decision-making task 
called the Tower of London. In this task, participants viewed computer-generated images of 
three differently colored balls each on a stick. They were presented with a before image as well 
as an after image in which the balls were arranged in a different order. Participants were asked to 
determine the least number of times that the balls needed to be switched in the before image to 
achieve the after image. It was found that although the response time was consistent across all 
groups, subjects who were administered THC made more incorrect responses than control 
subjects up to five and a half hours after administration (Ramaekers et al., 2006). The findings 
were dose-dependent, meaning that participants who were administered higher doses of THC 
made more numerous incorrect decisions and answered incorrectly for a longer period of time 
following administration than those who were administered lower doses of THC (Ramaekers et 
al., 2006). These results are in stark contrast to another study which found that marijuana users 
were not impaired in the Tower of London task following THC administration (Hart, van Gorp, 
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Haney, Foltin, & Fischman, 2001). 
Vadhan and colleagues (2007) conducted a study in which decision-making ability in 
marijuana users was assessed using the Iowa Gambling Task. In this task, participants were 
asked to repeatedly select cards from four different decks to potentially win hypothetical 
amounts of money. Two decks consistently yielded smaller gains with occasional smaller losses, 
while the other two decks consistently yielded larger gains with occasional larger losses. Overall, 
it would be more advantageous to select from the first two decks in terms of monetary gains. It 
was found that although subjects who were administered varying levels of THC exhibited 
prolonged response times, they did not make significantly more incorrect (disadvantageous) 
decisions than control subjects (Vadhan et al., 2007). 
Summary 
 While the literature is inconclusive regarding the effect size of impaired psychological 
impact in cannabis users, age at onset, frequency, quantity, and duration of use have been 
identified as potential predictors of cognitive disruption (Crean, Crane, & Mason, 2011). For 
instance, inexperienced users performed more poorly on attention tasks following THC 
administration than did frequent users, likely due to acquired THC tolerance in those who use 
regularly (Hart et al., 2001; Morrison et al., 2009). While working memory is similarly impaired 
in experienced and non-experienced users following THC administration, there seems to be no 
long-term effect of cannabis on working memory (Heishman et al., 1997; Miller et al., 1977; 
Pope & Yurgelun-Todd, 1996). Regarding impairment of decision-making, the literature 
suggests that regular cannabis users tend to have prolonged response times, but do not show a 
significant trend towards choosing incorrectly (Hart et al., 2001; Vadhan et al., 2007). In 
instances where cannabis users do make significantly more incorrect choices, it is hypothesized 
ANHEDONIA, DISCOUNTING, AND CANNABIS USE  17 
 
that this impairment is dose-dependent (Ramaekers et al., 2006). 
Behavioral Economics 
 Behavioral economics is an interdisciplinary field of research that applies key principles 
of economics to the study of behavior in an economic setting (Madden, 2000). Key principles of 
economics such as price, demand, alternative sources of reinforcement, and decreased valuation 
of delayed rewards are used to better understand decision-making (Madden, 2000). In behavioral 
economics, the standard economic model is applied in consideration with human beings’ natural 
tendency to make economically irrational decisions (Thorgeirsson & Kawachi, 2013). 
Psychological variables that may impede economically sound decision-making in humans 
include bounded rationality and bounded willpower (Thorgeirsson & Kawachi, 2013). When 
making decisions, humans are bound to their existing level of rationality in that economically 
irrelevant contextual influences inhibit the ability to view the situation with perfect clarity and 
consideration of the future (Thorgeirsson & Kawachi, 2013). Humans are also bound to their 
level of willpower in that they may succumb to immediate rewards in exchange for later 
consequences (Thorgeirsson & Kawachi, 2013). Overall, the discipline of behavioral economics 
takes human error into account when assessing decision-making behaviors in an economic 
setting. 
Delay Discounting 
One branch of behavioral economic research attempts to quantify impulsive decision-
making by studying delay discounting, or the preference for smaller, immediate rewards over 
larger, later rewards (Madden & Johnson, 2010). In this decision-making scenario, preference for 
the immediate reward is more impulsive because this choice pattern decreases the long-term rate 
of reward (Madden & Johnson, 2010). Rachlin and colleagues (1991) pioneered delay-
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discounting research in humans, presenting participants with the choice of receiving hypothetical 
amounts of money immediately or after specified delays ranging from one month to fifty years. 
While most participants chose the immediate reward when both the immediate and the delayed 
rewards were $1,000, responses began to differ as the immediate reward became smaller 
(Rachlin, Raineri, & Cross, 1991). As the survey proceeded, the immediate reward 
systematically decreased (e.g. $990 now vs. $1,000 in one month) until participants were 
eventually choosing between $1 now and $1,000 sometime in the future (Rachlin, Raineri, & 
Cross, 1991). The point at which the participant switches from selecting the full, delayed reward 
to the smaller, immediate reward is referred to as the indifference point (Rachlin, Raineri, & 
Cross, 1991). The amount of the offer at the indifference point is the discounted value of the 
delayed reward, indicating that the subject would reject any smaller reward amount and accept 
any larger reward amount (Madden & Bickel, 2010). According to the economic analysis of 
choices made in this scenario, a comparatively high indifference point indicates steeper 
discounting of rewards and serves as a measure of increased impulsivity (Rachlin, Raineri, & 
Cross, 1991). 
 In order to predict discounting rates over time, researchers have attempted to describe 
how the value of a reward declines as the delay to its delivery increases through fitting 
exponential and hyperbolic curves to empirical delay discounting functions (Madden & Johnson, 
2010). Classic economists devised the exponential equation of delay discounting, in which the 
value of a delayed reward should be discounted in a compounding fashion with each additional 
unit of delay (Madden & Johnson, 2010). While the exponential equation reflects the most 
economically rational discounting patterns, the hyperbolic discounting equation more accurately 
accounts for systematic deviations from rationality often observed in human participants 
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(Rachlin et al., 1991; Simpson & Vuchinich, 2000; Madden & Johnson, 2010), particularly in 
individuals with substance dependence (Bickel et al., 1999; Madden et al., 1999; Odum et al., 
2002). 
Delay Discounting and Cannabis Dependence 
 The literature regarding delay discounting is often targeted to substance-dependent 
populations, as these individuals frequently sacrifice later rewards such as improved health and 
decreased risk of legal repercussions for the immediate reward of a substance-induced high and 
prevention of withdrawal symptoms (Yi, Mitchell, & Bickel, 2010). As substance-dependent 
individuals repeatedly choose to consume the substance, it can be inferred that they value the 
immediate reinforcement of the substance more highly than the subjective value of abstinence 
(Yi, Mitchell, & Bickel, 2010). This decision-making behavior is indicative that substance-
dependent individuals may discount the value of future rewards more highly in other aspects of 
their lives as well (Yi, Mitchell, & Bickel, 2010). 
 While there is strong evidence for higher rates of discounting among tobacco, alcohol, 
cocaine, and other types of drug users (Yi, Mitchell, & Bickel, 2010), the literature is less 
extensive regarding discounting in cannabis users (Peters et al., 2013). One study involving 
adults with current marijuana dependence, former marijuana dependence, and no history of 
regular marijuana use found that individuals with current marijuana use showed a nonsignificant 
trend towards steeper discounting than the other two groups, indicating that marijuana-dependent 
individuals may show a more modest increase in discounting than users dependent on other 
drugs (Johnson et al., 2010). In a subsequent study, although delay discounting was not 
correlated with marijuana use, increased discounting was associated with decreased readiness to 
change problematic marijuana use patterns (Peters et al., 2013). Overall, the current literature 
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suggests that marijuana dependence may be weakly associated with delay discounting, and this 
association is not as strong as that observed with other drugs with higher abuse-related properties 
(Johnson et al., 2010). 
 
Cannabis Dependence and Mental Illness Comorbidity 
 Individuals diagnosed with substance use disorder are about twice as likely to suffer from 
a comorbid mental illness compared to general respondents (National Institute on Drug Abuse 
[NIDA], 2010). In 2010, NIDA reported that roughly seventeen percent of respondents with 
cannabis use disorder also suffered from any mood disorder, while about fifteen percent also 
suffered from any anxiety disorder. While the correlation between cannabis use disorder and 
comorbid mental illness is clear, their temporal relationship is a subject of controversy. In some 
cases, individuals may use cannabis as a coping mechanism for mental illness, whereas other 
individuals may experience the incidence of adverse psychological symptoms resulting from 
cannabis use (Dakwar et al., 2011). 
Depression  
 In 2015, nearly seven percent of adults in the United States reported experiencing at least 
one major depressive episode (NIDA, 2015). According to the Diagnostic and Statistical Manual 
of Mental Disorders V, major depression is a mood disorder often characterized by feelings of 
sadness, hopelessness, or worthlessness, decreased ability to focus and make decisions, disrupted 
sleeping patterns, change in weight or appetite, and fatigue or loss of energy (Uher, Payne, 
Pavlova, & Perlis, 2014). Perhaps among the most characteristic symptoms of depression is loss 
of pleasure and interest in most activities, also referred to as anhedonia (Pizzagalli, 2014). There 
is evidence suggesting that major depressive disorder is marked by weakened dopamine 
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transmission, which may account for the reduced response to pleasurable stimuli in anhedonic 
individuals (Pizzagalli, 2014). Furthermore, this neurobiological imbalance is thought to 
contribute not only to the anhedonic states of depressed individuals, but also to the drug abuse 
patterns of substance-dependent individuals (Lazenka & Hutsell, 2017). 
The literature regarding depression among marijuana users remains inconclusive in terms 
of prevalence as well as order of occurrence (Grant et al., 1995; Brook et al., 1998; Harder et al., 
2006; Repetto et al., 2008; Johnson et al., 2009; Horwood et al., 2012). For instance, Johnson 
and colleagues found no evidence of correlation between marijuana use and depressive 
symptoms (2009), whereas Grant and colleagues found that those meeting criteria for cannabis 
abuse or dependence were over six times more likely to also meet criteria for major depressive 
disorder (1995). Similarly, a ten-year longitudinal study found that early depressive symptoms 
did not predict subsequent marijuana use (Brook, Cohen, & Brook, 1998), while another 
prospective study found that depressive symptoms in adolescent males predicted marijuana use 
later in life (Repetto, Zimmerman, & Caldwell, 2008). The last two studies referenced examined 
depressive symptoms as the causal variable for marijuana use, whereas other researchers have 
conversely examined marijuana use as a potential predictor of depression (Harder, Morral, & 
Arkes, 2006). In one study, it was found that marijuana use did not significantly predict the 
development of depressive symptoms (Harder, Morral, & Arkes, 2006). A later study supported 
these results, concluding that early-onset problematic cannabis use in adolescents did not predict 
the onset of depression in young adulthood (Harder, Stuart, & Anthony, 2008). Conversely, a 
fifteen-year longitudinal study found evidence of a causal relationship between frequent 
adolescent cannabis use and development of depression in adulthood (Horwood et al., 2012). 
Evidence of co-occurring marijuana use and depressive symptoms has been documented, but 
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whether there is a reliable association between the two remains unclear. Additionally, evidence 
of a temporal relationship is inconclusive; it is unknown whether marijuana use may produce or 
exacerbate depressive symptoms, or if depressed individuals may be using marijuana as a coping 
mechanism (Bovasso, 2001). 
While the temporal relationship between depression and cannabis use is unclear, there is 
evidence in support of the theory that high prevalence of use among depressed individuals is best 
explained by a self-medication motivating factor (Denson & Earleywine, 2006; Walsh et al., 
2013). A study of over six hundred Canadian adults who used cannabis for therapeutic purposes 
found that sixty-seven percent of all participants reported using cannabis to relieve symptoms of 
depression (Walsh et al., 2013). Furthermore, Denson and Earleywine employed the largest 
known survey of marijuana and depression with over 4,400 participants and found that marijuana 
use may alleviate depressive symptoms (2006). Despite similar score ranges on all depression 
subscales, participants who used marijuana daily reported less depressed mood and more positive 
affect (positive moods such as joy, interest, and alertness) than those who did not use at all 
(Denson & Earleywine, 2006). 
 Overall, the literature regarding comorbid marijuana use and major depressive disorder is 
largely inconclusive. There is some research to support the hypothesis that marijuana use and 
depression are correlated, while other studies have found no correlation between the two. 
Additionally, researchers have yet to come to a consensus on the temporal relationship between 
marijuana use and depression in cases where associations have been observed. Some studies 
suggest that cannabis use may foster depressive symptoms, while other researchers adhere to the 
self-medication hypothesis in which depressed individuals use cannabis for therapeutic purposes.  
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Depression and Delay Discounting 
Major depressive disorder is largely characterized by feelings of hopelessness, a negative 
view of the future, and impaired reward processing (Pulcu et al., 2014). Accordingly, delay 
discounting procedures are often employed to measure future-directed thinking in depressed 
individuals (Pulcu et al., 2014). An existing theory is that due to a hopelessness for the future, 
depressed individuals are more likely to discount the value of future rewards and consequently 
settle for smaller, more immediate rewards (Beck, 1979). One study involving participants with 
current depression, past depression, and no history of depression found that those with current 
depression discounted future rewards at significantly higher rates than those in the other two 
groups (Pulcu et al., 2014). An association was also observed between steep discounting and 
feelings of hopelessness within the currently depressed group, supporting the theory that 
depressed individuals may discount the value of future rewards due to a bleak outlook of the 
future (Pulcu et al., 2014). 
 Contrary to the theory that depressed individuals discount future rewards more steeply 
because of hopeless feelings, there is also evidence of an association between major depressive 
disorder and lower discounting of future rewards (Lempert & Pizzagalli, 2010). One study 
employed the Snaith-Hamilton Pleasure Scale to assess anhedonia levels in thirty-six 
undergraduate participants (Lempert & Pizzagalli, 2010). It was observed that increased 
anhedonia was significantly associated with lower levels of delay discounting, meaning that 
anhedonic individuals were more likely to prefer the larger, delayed reward rather than the 
smaller, immediate reward (Lempert & Pizzagalli, 2010). These findings support the existing 
theory that depressed individuals may discount less because of blunted responses to immediate 
rewards, a key characteristic of anhedonia (e.g. Berenbaum & Oltmanns, 1992; Wacker et al., 
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2009; Lempert & Pizzagalli, 2010). 
 A later study assessed delay discounting behaviors in depressed individuals who also 
suffered from comorbid substance use disorder (Moody, Franck, & Bickel, 2016). As noted 
previously, substance-dependent individuals express a tendency to discount future rewards more 
steeply than healthy controls (Madden & Bickel, 2010). In this study, it was observed not only 
that those with substance use disorder discounted future rewards more than healthy controls, but 
also that those with comorbid depression and anti-social personality disorder discounted more 
steeply those with substance use disorder alone (Moody, Franck, & Bickel, 2016). Although 
substance use disorder combined with major depressive disorder alone was not significantly 
associated with steeper discounting, the finding that combined depression, anti-social personality 
disorder, and substance use disorder were highly correlated with steeper discounting suggests an 
additive effect of psychological illnesses (Moody, Franck, & Bickel, 2016). 
 Although the literature remains inconclusive regarding the direction of association 
between major depressive disorder and discounting, there is clear evidence that depressed 
individuals tend to discount the value of future rewards at a systematically different rate than that 
of healthy controls (Lempert & Pizzagalli, 2010; Pulcu et al., 2014). One theory views the 
depressive symptom of hopelessness for the future as the explanatory variable for depressed 
individuals’ tendency to discount the value of future rewards (Pulcu et al., 2014). Conversely, an 
opposing theory states that anhedonia, or general lack of response to immediate, rewarding 
stimuli, accounts for depressed individuals’ preference for later rewards (Berenbaum & 
Oltmanns, 1992; Wacker, Dillon, & Pizzagalli, 2009; Lempert & Pizzagalli, 2010). Additionally, 
the literature suggests that psychological illnesses may exacerbate steeper discounting, namely in 
individuals with comorbid substance use disorder (Moody, Franck, & Bickel, 2016). 
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The Present Study 
 The existing literature suggests that there may be an independent association between 
problematic cannabis use and incidence of depressive symptoms (Grant et al., 1995; Repetto et 
al., 2008; Horwood et al., 2012). Furthermore, there is conclusive evidence that depressive 
symptoms, particularly hopelessness and anhedonia, are associated with delay discounting 
tendencies significantly differing from that of healthy controls (Lempert & Pizzagalli, 2010; 
Pulcu et al., 2014). Finally, there is strong evidence of steeper discounting of delayed rewards 
among tobacco, alcohol, and cocaine users (Yi, Mitchell, & Bickel, 2010), but the literature 
regarding discounting among cannabis users is less extensive (Peters et al., 2013). Considering 
these observations, the purpose of the present study is to determine the associations between 









 Participants in this study included 329 undergraduate students at East Carolina 
University. Participants included 197 females, 131 males, and one unspecified between the ages 
of 18 and 30. Participants were recruited using the Department of Psychology’s Experimentrak 
software, which invites all students currently enrolled in introductory psychology courses to 
participate in the study. Participants were informed that participation in the study was completely 
anonymous, voluntary, and had no bearing on their academic standing. 
Design 
 The research design of this study was non-experimental and correlational, as it explored 
the relationships between problematic cannabis use, depressed mood, and impulsivity. 
Problematic cannabis use was studied as the predictor variable for potential anhedonic symptoms 
and impulsivity traits. 
Measures and Procedure 
 All data were collected using a compilation of self-report surveys administered through 
Qualtrics, a web-based survey tool (Qualtrics, Provo, UT). The first section of the survey 
assessed marijuana use patterns by asking participants to indicate their age of first marijuana use 
and the amount of marijuana typically used per week in ounces. Participants who indicated no 
marijuana use were redirected to the next section of the survey. Participants who indicated any 
level of marijuana use were then assessed for cannabis dependence using the DSM-V Non-
Alcohol Psychoactive Substance Use Disorders criteria. Participants selected yes or no to each of 
five items to indicate the presence or absence of various aspects of tolerance and withdrawal. 
Participants were then asked to complete the Marijuana Problems Scale (MPS), a 19-item 
questionnaire measuring the level of interpersonal, occupational, medical, legal, and personal 
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problems caused by marijuana use. Participants responded to each item by indicating that 
marijuana causes them to experience no problem (0), a minor problem (1), or a serious problem 
(2) in the given area. 
 The second section of the survey assessed the hedonic experience of each participant. 
Participants were first asked to indicate whether they have been clinically diagnosed with 
depression, and were then presented with the Snaith-Hamilton Pleasure Scale (SHAPS). The 
SHAPS is a 14-item questionnaire measuring the level of pleasure experienced over four hedonic 
domains: interest/pastimes, social interaction, sensory experience, and food/drink (Snaith et al., 
1995). Each item describes a scenario that hedonic individuals would likely find enjoyable. 
Participants were asked to indicate the degree to which they agreed that they would find pleasure 
in each experience using a four-point Likert-type scale ranging from strongly disagree to 
strongly agree. Since the SHAPS is intended to measure pleasure, the present study used a 
reverse-scoring technique so that responses would reflect anhedonia rather than pleasure. 
Specifically, strongly disagree was scored as a four (low pleasure, high anhedonia) while 
strongly agree was scored as a one (high pleasure, no anhedonia). 
 The third section of the survey assessed choice impulsivity of each participant using a 
series of delay discounting tasks. Participants were asked to indicate whether they would prefer 
to receive a smaller amount of money immediately or a larger amount of money after a specified 
delay. The maximum hypothetical amount offered was $300, and delays used were one week, 3 
weeks, 10 weeks, 30 weeks, 100 weeks, and 300 weeks. Indifference points were identified by 
the point at which each participant switched from selecting the delayed reward to the immediate 
reward or vice versa, indicating that the immediate and delayed amounts are perceived to be of 
the same value due to the delay. Indifference points were then used to estimate the extent to 
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which the reward was discounted in a least squares nonlinear regression. The delay discounting 
portion of the survey served as an integrated attention-check mechanism; subjects who indicated 
only one indifference point were considered to be paying attention and therefore providing 
accurate feedback, whereas subjects who switched from choosing the immediate reward to the 
delayed reward multiple times were thought to be providing inauthentic feedback and were 
therefore excluded from the data set. 
 Finally, participants were asked to provide demographic data including date of birth, 
biological sex, racial/ethnic background, current cumulative grade point average, and number of 
undergraduate credit hours currently completed. After completing the survey, participants were 




Table 1 (page 30) describes the survey sample based on gender, ethnicity, age, and 
marijuana ounces used per week. 60 percent of participants (n=197) were female and 40 percent 
(n=131) male. Twenty-four percent of participants (n=78) were non-white (Native American, 
Asian American, African American, Latino, and Pacific Islander), while 76 percent (n=251) were 
white. The mean age of all participants was 18.69 years. Table 1 also categorizes participants 
according to ounces of marijuana used per week, which is discussed further below. 
Additional participant demographics are depicted in Figure 1 (page 31); the left graph 
indicates the number of participants who fell into each age range. The majority of participants 
were between the ages of 18 and 20. The middle graph indicates the number of participants who 
reported currently having each approximate GPA. Nearly half of all participants indicated having 
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an approximate GPA of 3.5. The right graph depicts the number of participants who have 
completed within each range of credit hours. The majority of participants (74%) had completed 
between 0 and 15 credit hours, meaning that most participants were first-semester freshmen. 
Marijuana Use Frequency 
 Seventy percent of participants (n=232) indicated having used marijuana at any point 
during their lives, while just over 30 percent (n=111) indicated current, regular marijuana use. Of 
the participants who indicated current marijuana use, 66 percent (n=74) use one-sixteenth of an 
ounce or less per week and 25 percent (n=28) use about one-eighth of an ounce per week. Only 4 
percent (n=4) use one-quarter of an ounce per week and only 5 percent (n=5) use one-half of an 
ounce or more per week. 
 The graphs shown in Figure 2 (page 32) depict the relationships between amount of 
marijuana used per week and other use-related variables. The upper left graph illustrates the age 
of first marijuana use for participants in each weekly use category. The mean age of first use for 
participants who use one-quarter of an ounce per week was 16.5, while the mean age of first use 
for all other weekly use categories is approximately 15. The upper right graph depicts the DSM-
V Cannabis Use Disorder criteria met for participants in each weekly use category. A positive 
trend was observed between the two variables, suggesting that increased marijuana use per week 
was associated with more dependence characteristics. The lower left graph displays scores on the 
MPS for participants in each weekly use category. There was a modest positive association, 
suggesting that increased marijuana use per week may result in a higher incidence of marijuana-
related problems. Finally, the lower right graph illustrates scores on the SHAPS for participants 
in each weekly use category. A modest negative relationship was observed, indicating that 
increased marijuana use per week was associated with blunted responses to pleasurable stimuli.  
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Variable n (%) 
Gender  
     Female 197 (60) 
Ethnicity (Non-White) 78 (24) 
Age   18.69 
Marijuana ounces used per week  
     Never 97 (29) 
     Not Current 121 (37) 
    1/16th 74 (22) 
    1/8th 28 (9) 
     1/4th 4 (1) 
     > 1/4th  5 (2) 
 
Table 1. The number and percent of participants by gender, ethnicity, mean age, and marijuana 
ounces used per week.  







Figure 1. Left: the number of participants in each age range. Middle: the number of participants who reported each approximate GPA. 
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Figure 2. Upper left: approximate amount of marijuana used per week and age of first marijuana 
use. Upper right: approximate amount of marijuana used per week and DSM-V CUD criteria. 
Lower left: approximate amount of marijuana used per week and MPS score. Lower right: 
approximate amount of marijuana used per week and anhedonia score. 
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Data Analysis 
 Participants who indicated using one quarter of an ounce of marijuana per week and one 
half an ounce or more per week were excluded from data analysis due to few participants in each 
group. A series of bivariate correlations were calculated to determine the correlations among all 
variables, summarized in Table 2 (page 34). The correlation between age of first marijuana use 
and DSM-V CUD criteria was r(262) = 0.27, p < 0.05. The correlation between age of first 
marijuana use and MPS score was r(262) = 0.41, p < 0.05. The correlation between DSM-V 
CUD criteria and MPS score was r(262) = 0.73, p < 0.05. The correlation between DSM-V CUD 
criteria and ounces of marijuana used per week was r(262) = 0.67, p < 0.05. The correlation 
between ounces of marijuana used per week and age of first marijuana use was r(262) = 0.54, p < 
0.05. The correlation between ounces of marijuana used per week and MPS score was r(262) = 
0.88, p < 0.05. Insignificant correlations were observed among all remaining intercorrelations. 
 A multiple regression analysis, summarized in Table 3 (page 35), was conducted to 
determine if marijuana ounces used per week or anhedonia scores significantly predicted delay 
discounting scores. Neither marijuana use amount nor anhedonia were significant predictors of 
discounting. However, a significant quadratic trend was observed for marijuana use amount on 
delay discounting (β = 61.29, p < 0.04). The multiple regression models are displayed in Figure 3 
(page 35). 
   





Table 2. Summary of correlations for age of first marijuana use, DSM-V criteria for Cannabis 
Use Disorder, Marijuana Problems Scale scores, ounces of marijuana used per week, anhedonia 
scores, and delay discounting. 
  
 Variable 1. 2. 3. 4. 5. 6. 
  1st Use DSM  MPS AMT SHPS DD 
1. Age 1st Use --      
2. DSM CUD 0.27* --     
3. Marijuana Problem Scale 0.41* 0.73* --    
4. Use Amount (ounces/week) 0.54* 0.67* 0.88* --   
5. Anhedonia Score (SHPS) 0.10 0.09 0.04 0.08 --  
6. Delay Discounting -0.07 -0.03 -0.03 0.01 0.02 -- 
 








Figure 3. Multiple regression models 
  
       
 Predictor β  t  p 
Model 1       
 Marijuana Use Amount 0.03  0.03  0.97 
 Anhedonia Score 0.002  0.32  0.75 
 MJ*Anhedonia Interaction 0.07  0.13  0.57 
Model 2       
 Marijuana Use Amount -6.66  -1.9  0.056 
 (MJ Use Amt)2 61.29  2.05  0.04 
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Discussion 
 The current literature indicates that depressive symptoms, namely anhedonia, may be 
more prevalent among cannabis-dependent populations (Bovasso, 2001). Major depressive 
disorder has also been associated with some measures of impulsivity (Beck, 1979; Lempert & 
Pizzagalli, 2010; Pulcu et al., 2014). Furthermore, the literature is conclusive in that individuals 
dependent upon substances including tobacco, nicotine, and cocaine score higher on measures of 
impulsivity, but the research is less extensive regarding impulsivity among cannabis-dependent 
individuals (Yi et al., 2010; Peters et al., 2013). Accordingly, the present study employed a delay 
discounting task to assess impulsivity in cannabis users and determine the association between 
cannabis use, anhedonia, and discounting. 
Overall, no statistically-significant correlations were observed between anhedonia and 
problematic marijuana use, delay discounting and problematic marijuana use, or anhedonia and 
delay discounting. However, multiple statistically-significant correlations were observed 
particularly among marijuana use measures. The following sections compare these findings to 
the existing literature and outline potential explanations for discrepancies. 
Anhedonia and Delay Discounting 
The existing literature indicates that depressed individuals tend to discount at 
systematically different rates compared to healthy controls. Depressed individuals have been 
shown to discount the value of future rewards more steeply, perhaps due to a sense of 
hopelessness for the future (Beck, 1979; Pulcu et al., 2014), as well as less steeply, likely due to 
a lack of pleasure in response to immediate rewards (Berenbaum & Oltmanns, 1992; Wacker et 
al., 2009; Lempert & Pizzagalli, 2010). The present study sought to explore the steeper 
discounting theory, as it assessed the anhedonia (lack of pleasure) aspect of depression. The 
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present findings are neither consistent nor inconsistent with the existing literature, as depressed 
individuals were not present in the sample. The present study assessed a general sample of 
college students lacking in high anhedonia scores, while past research involved participants from 
clinically depressed populations. 
Cannabis Use and Delay Discounting 
The present study observed no significant association between problematic marijuana use 
and delay discounting, although it is important to note that participants who indicated using the 
greatest amounts of marijuana per week were excluded due to a low number of participants in 
these groups. Nonetheless, this lack of association is consistent with the limited literature on 
discounting in marijuana users, which indicates that there is little to no association (Johnson et 
al., 2010; Peters et al., 2013). Cannabis differs from other drugs of abuse in that individuals 
dependent on substances including tobacco, alcohol, and cocaine have been shown to discount 
the value of future rewards more steeply (Yi, Mitchell, & Bickel, 2010). The present findings 
suggest that cannabis-dependent individuals may be less impulsive than individuals dependent 
on substances with higher abuse potential. 
Anhedonia and Cannabis Use 
Previous findings have also indicated that depressive symptoms are more prevalent 
within cannabis-dependent populations (Grant et al., 1995; Repetto et al., 2008; Horwood et al., 
2012). The present study failed to observe this association, likely due to the low number of 
participants in high marijuana use groups as well as high anhedonia groups. Conversely, other 
studies have also found no correlation between cannabis use and depressive symptoms (Brook et 
al., 1998; Harder et al., 2006; Harder et al., 2008; Johnson et al., 2009). 
One explanation for the lack of association between cannabis use and depression may be 
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related to the use motives of cannabis-dependent populations; it has been theorized that 
depressed individuals use cannabis as a form of self-medication (Bovasso, 2001; Denson & 
Earleywine, 2006; Wash et al., 2013). In this case, marijuana users would exhibit fewer 
depressive symptoms because of marijuana use rather than exacerbated depressive symptoms 
(Denson & Earleywine, 2006). In the present study, assessing participants for marijuana use 
motives would have helped to determine if self-medication motives influenced the lack of 
association between cannabis use and anhedonia. 
 While the multiple regression analysis revealed that neither marijuana use amount nor 
anhedonia were significant predictors of delay discounting, a significant quadratic trend was 
observed for weekly marijuana use amount on discounting. Although the present sample is 
lacking participants in higher use groups, evidence of a dose-dependent relationship between use 
amount and discounting can be observed in Figure 3 (page 35). This is an important observation 
because traditional behavioral pharmacology studies the dose of any substance as the primary 
variable for determining behavioral outcomes (Byrne & Poling, 2000). The quadratic trend 
observed in the present sample indicates that a dose-dependent effect may be present in a sample 
with a wider range of weekly use amounts, overall suggesting that marijuana use amount (dose) 
could serve as a predictor for discounting. 
Marijuana Use Measures 
 The correlational analysis among all variables revealed that statistically-significant 
correlations were present primarily among marijuana use measures. Specifically, weekly 
marijuana use amount was significantly correlated with age of first marijuana use, DSM-V 
criteria for cannabis use disorder, and MPS score. MPS score was also significantly correlated 
with age of first marijuana use and DSM-V CUD criteria. Finally, DSM-V CUD was 
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significantly correlated with age of first marijuana use. 
 The fact that weekly marijuana use amount was significantly associated with three of the 
other marijuana use measures is an important finding because it serves as further support for the 
dose-dependent effect. In other words, the more marijuana an individual uses per week, the more 
likely they are to fulfill more criteria for cannabis use disorder and experience more marijuana-
related problems. This finding could be useful for future cannabis research because studying 
dose as the predictor variable could lead to discoveries regarding behavioral effects of cannabis 
over a range of dose amounts. 
Study Limitations 
 Limitations of the present study include expectancy theory, which refers to the fact that 
measures of marijuana use were presented to participants before completing the delay 
discounting tasks. Research has shown that participants who are administered a THC placebo 
discount less as a means of compensating for the expected effects of THC (Metrik et al., 2012). 
Expectancy theory may have had a similar effect in the present study, motivating participants to 
make less impulsive choices following disclosure of their marijuana use patterns. Further, the 
discounting task was not self-adjusting according to choices made, which is a feature that is 
typically used in modern discounting research. Finally, the nature of the study did not allow for a 
high degree of environmental control. The researchers were unable to control the setting in 
which the participants chose to complete the survey, nor the sobriety status of participants at the 
time of completion; in other words, participants may have completed the survey in a distracted 
environment, and it is possible that current marijuana users may have been under the influence at 
the time of participation. 
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Conclusion 
Although no statistically-significant associations were observed among anhedonia and 
cannabis use, discounting and cannabis use, or anhedonia and discounting, the present study 
nonetheless made valuable contributions to the cannabis research literature. The data analysis 
revealed the importance of marijuana use amount as a predictor variable for behavioral 
outcomes. The present literature tends to overlook the importance of cannabis dose although 
traditional behavioral pharmacology has recognized dose amount as a critical component of drug 
research (Byrne & Poling, 2000). Future cannabis research should study marijuana use amount 
as the predictor variable in order to better understand the behavioral outcomes for users across a 
range of use amounts. 
The present findings regarding discounting among cannabis users support the existing 
literature, which indicates that little to no association exists. Since delay discounting tasks serve 
as a measure of impulsivity, the overall implication is that cannabis users are not more impulsive 
than non-drug users. Cannabis seems to differ from other drugs of higher abuse potential 
including nicotine, tobacco, and cocaine, which have been associated with more impulsive users 
(Yi, Mitchell, & Bickel, 2010). Additionally, since cannabis was not associated with anhedonia, 
the present study also found preliminary evidence to support the existing theory that cannabis 
users may be self-medicating for depressive symptoms (Bovasso, 2001; Denson & Earleywine, 
2006; Wash et al., 2013). 
Although further research is needed to support these findings, the implication that 
cannabis users are not as impulsive as users of drugs with higher abuse potential along with the 
preliminary evidence that individuals may be relieving depressive symptoms through cannabis 
use serve to support the broad argument that the status of cannabis as a Schedule I drug should 
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be reconsidered (DEA). The DEA classifies Schedule I drugs as those that have high abuse 
potential and do not provide any approved medical benefits. However, there is expanding 
evidence that cannabis differs from drugs of higher abuse potential in terms of behavioral 
outcomes. In addition, there is expanding support for the theory that cannabis use could serve to 
relieve depressive symptoms. Future research should examine the use motives of cannabis-
dependent individuals in order to identify instances of self-medication and potentially provide 
support for the rescheduling of cannabis.  
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